COVID-19 taught us many different things, including the fact that we were not as well prepared as we should have been to fight that pandemic. That's why we are preparing better for the next pandemic, because there will be a new pandemic. It's not “if”; it is “when”.
That's why we have put into place all sorts of measures, including changes in clinical trial funds to expedite and facilitate the use of clinical trials to test new drugs. That's why we have allowed rolling submissions for the assessment of drugs, again through the important regulatory improvements that were made during COVID-19. That's why we're investing in the National Research Council and the strategic science fund. That's why we're investing in a pharmacare pilot with Prince Edward Island. That's why we're investing in Moderna, Sanofi, AstraZeneca and many many other production, biomanufacturing, and research and development places and environments in Canada.
A lot of different things are moving on. We need to do that because, as you just said, there's a risk that all sorts of pandemics and epidemics, including influenza, may occur in the future.